ABVC BIOPHARMA, INC. ABVC
breakthrough products and technologies to combat various diseases through efficient industrial manufacturing. Biotechnology is an important
business sector in the world's economies and is vital to human health. Companies engaged in biotechnology generally require
large amounts of capital investment for their research & development activities. Developing and commercializing a new drug or medical
device may take up to tens of years. ABVC ("we" or the "Company") is an early-stage biotechnology company with
Last close
1.04
2026-10-23
Market cap
$27.7M
2026-06-30 share count
52-week range
0.71 - 3.06
Valuation FY2025 figures against the last close
P/S93.7x
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS-0.39
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $296.0K | $0 | $152.4K | $969.8K | $355.8K | $483.0K | $701.7K | $7.0K | — | — |
| Cost of revenue | — | $763 | $302.0K | $286.4K | $5.1K | $18.7K | $20.1K | $185.3K | — | $32 |
| Gross profit | — | $508.8K | -$149.6K | $683.4K | $350.7K | $464.3K | $681.6K | -$178.3K | — | -$32 |
| R&D | $121.1K | $179.3K | $1.1M | $2.7M | $1.0M | $549.7K | $1.0M | $988.7K | $3.2M | $10.0M |
| SG&A | $2.9M | $2.3M | $5.4M | $6.1M | $5.7M | $4.3M | $3.1M | $1.6M | $811.7K | $599.3K |
| Total operating expenses | $7.2M | $5.2M | $6.6M | $15.8M | $12.1M | $9.0M | $4.1M | $2.6M | $4.1M | — |
| Operating income | -$7.2M | -$4.7M | -$6.8M | -$15.1M | -$11.7M | -$8.5M | -$3.5M | -$2.8M | -$4.1M | -$11.0M |
| Interest expense | $415.9K | $825.9K | $1.3M | $294.0K | $227.2K | $405.0K | $482.0K | $462.8K | $103.5K | $10.2K |
| Pre-tax income | -$8.4M | -$5.4M | -$8.0M | -$15.5M | -$11.2M | -$10.8M | -$4.0M | -$6.4M | -$4.2M | -$11.0M |
| Income tax | $24.2K | $110.5K | $256.0K | $797.8K | $825.0K | $220.4K | $77.0K | $365.1K | $830 | $836 |
| Net income | -$7.9M | -$4.9M | -$7.8M | -$16.4M | -$12.8M | -$10.6M | -$3.9M | -$6.1M | -$4.2M | -$11.0M |
| EPS, basic | -0.39 | -0.42 | -1.80 | -5.19 | -0.51 | -0.50 | — | -0.02 | -0.02 | -0.06 |
| EPS, diluted | -0.39 | -0.42 | -1.80 | -5.19 | -0.51 | -0.50 | -0.21 | -0.48 | -0.02 | -0.06 |
| Shares, diluted (wtd. avg.) | 20.1M | 11.7M | 4.3M | 3.2M | 25.1M | 19.7M | — | 213.9M | 213.3M | 194.0M |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $681.5K | $248.4K | $716.8K | $1.4M | $6.6M | $5.0M | $160.4K | $242.8K | $406.8K | $18.6K |
| Short-term investments | $64.4K | $64.7K | $79.3K | $75.8K | $108.1K | — | — | — | — | — |
| Receivables | — | — | $1.5K | $98.3K | $280.7K | $159.7K | — | — | — | — |
| Inventory | — | — | — | — | $26.0K | — | — | $1.3K | — | — |
| Total current assets | $2.5M | $2.2M | $1.7M | $3.0M | $7.7M | $6.2M | $878.2K | $566.5K | $2.6M | $173.5K |
| Property, plant and equipment | $12.8M | $511.1K | $569.3K | $574.0K | $525.9K | $514.8K | $520.9K | $510.1K | — | — |
| Total assets | $21.1M | $7.5M | $7.8M | $9.6M | $13.7M | $11.6M | $6.9M | $5.9M | $2.6M | $177.4K |
| Accounts payable | — | — | — | — | — | $23.0K | $24.0K | — | — | — |
| Short-term debt | $755.5K | $840.3K | $899.2K | $1.9M | $1.6M | $1.6M | $1.9M | $899.2K | — | — |
| Total current liabilities | $6.2M | $6.6M | $6.1M | $5.5M | $3.7M | $4.8M | $6.8M | $11.0M | $4.4M | — |
| Total liabilities | $7.8M | $6.8M | $6.5M | $6.3M | $4.8M | $8.9M | $7.1M | $11.3M | $4.4M | $6.6M |
| Retained earnings | -$76.9M | -$68.9M | -$64.0M | -$54.9M | -$38.5M | -$25.6M | -$15.9M | -$12.2M | -$15.8M | -$11.3M |
| Total equity | $11.1M | $1.2M | $1.3M | $3.2M | $8.9M | $2.7M | -$124.8K | -$5.3M | $703.3K | -$6.5M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$3.0M | -$1.8M | -$4.2M | -$7.4M | -$7.6M | -$4.6M | -$3.1M | -$900.5K | -$1.5M | -$3.5M |
| Depreciation and amortisation | $25.3K | $32.0K | $28.5K | $23.8K | $12.0K | $37.1K | $55.1K | $43.6K | — | — |
| Stock-based compensation | $4.1M | $2.8M | $185.9K | $7.0M | $5.3M | $4.1M | $22.3K | $28.8K | $155.4K | $398.0K |
| Capital expenditure | — | — | $21.2K | $119.7K | $17.5K | — | — | — | — | — |
| Investing cash flow | -$1.2M | — | -$360.2K | -$1.7M | -$806.0K | -$225.4K | -$35.3K | -$156.4K | — | — |
| Financing cash flow | $4.6M | $2.0M | $3.9M | $4.0M | $10.0M | $9.6M | $3.1M | $896.9K | $1.6M | $2.7M |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001213900-26-023063.
Plot the figures US dollars
Income statement
Revenue
Cost of revenue
Gross profit
R&D
SG&A
Total operating expenses
Operating income
Interest expense
Pre-tax income
Income tax
Net income
EPS, basic
EPS, diluted
Shares, diluted (wtd. avg.)
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | $7.0K | $701.7K | $483.0K | $355.8K | $969.8K | $152.4K | $0 | $296.0K |
| Gross profit | -$32 | — | -$178.3K | $681.6K | $464.3K | $350.7K | $683.4K | -$149.6K | $508.8K | — |
| Net income | -$11.0M | -$4.2M | -$6.1M | -$3.9M | -$10.6M | -$12.8M | -$16.4M | -$7.8M | -$4.9M | -$7.9M |
Recent filings and events
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Acquisition or disposal completed A purchase or sale of a significant business or asset has closed. Item 2.01
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Other event Item 8.01
- Auditor changed The company changed auditors. Sometimes routine; historically one of the more reliable warnings that something is wrong. Item 4.01
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Accounts can no longer be relied on The company is telling investors that figures it has already published are wrong. Rare, and about as direct as a filing gets. Item 4.02
- Unregistered share sale Shares issued outside a registered offering. Dilution, and for a small company often the way it is funded. Item 3.02
- Results announced Item 2.02
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.20T | 55.5x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $635.76B | 23.9x | 6.0% |
| ABBV | AbbVie Inc. | $504.76B | 121.0x | 8.6% |
| MRK | Merck & Co., Inc. | $358.41B | 20.0x | 1.3% |
| ABT | ABBOTT LABORATORIES | $180.63B | 27.9x | 5.7% |
| PFE | PFIZER INC | $171.16B | 22.1x | -1.6% |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $132.80B | 34.2x | 8.9% |
| BMY | BRISTOL MYERS SQUIBB CO | $125.59B | 17.8x | -0.2% |